Nearly every drug may cause changes to ocular tissues through a variety of mechanisms. Medication overdoses, drug—drug interactions but also chronic administration of medications at the recommended doses may lead to ocular toxicity. The ocular side effects, screening for eye toxicity and treatment guidelines for anti-inflammatory and immunosuppressive drugs commonly used by rheumatologists are reviewed herein.
Rousseau GG, Baxter JD, Tomkins GMGlucocorticoid receptors: relations between steroid binding and biological effects. J Mol Biol1972; 67: 99-115.
2.
Chrousos GPThe hypothalamic-pituitary-adrenal axis and immune-mediated inflammation . N Engl J Med1995; 332: 1351-1362.
3.
Carnahan MC, Goldstein DAOcular complications of topical, peri-ocular, and systemic corticosteroids . Curr Opin Ophthalmol2000; 11: 478-483.
4.
Waterbury L. , Kunysz EA, Beuerman R.Effects of steroidal and non-steroidal anti-inflammatory agents on corneal wound healing. J Ocul Pharmacol1987; 3: 43-54.
5.
Haimovici R. , Gragoudas ES, Duker JS, et al. Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Ophthalmology1997; 104: 1653-1660.
6.
Purdy EP, Ajimal GSVision loss after lumbar epidural steroid injection. Anesth Analg1998; 86: 1191-1122.
Cousins MJ, Bridenbaugh PONeural blockade in clinical anesthesia and management of pain. 2nd edn. JB Lippincott; 1988, pp. 946-950.
10.
Fraunfelder FTHormones and agents affecting hormonal mechanisms. In: Fraunfelder FT (ed.), Drug-induced ocular side effects and drug interactions. Williams & Wilkins ; 1996. p. 288-290.
11.
Tripathi RC , Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk . Drugs Aging1999; 15: 439-450.
12.
Black RL, Oglesby RB, von Sallman L., et al. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA1960 ; 174: 166-171.
13.
Hanania NA, Chapman KR, Kesten S.Adverse effects of inhaled corticosteroids. Am J Med1995; 98: 196-208.
14.
Dluhy RGEffect of inhaled beclomethasone dipropionate and budesonide on adrenal function, shin changes and cataract formation. Respir Med1998; 92: 15-23.
Maiorca R., Cristinelli L., Brunori G., et al. Prospective controlled trial of steroid withdrawal after six months in renal transplant patients treated with cyclosporine. Transplant Proc1988; 20: 121-125.
17.
Tarantino A. , Aroldi A., Stucchi L., et al. A randomized prospective trial comparing cyclosporine monotherapy with triple drug therapy in renal transplantation . Transplantation1991; 52: 53-57.
18.
Ponticelli S., Pisani F., Montagnino G., et al. A randomized study comparing cyclosporine alone versus double and triple therapy in renal transplants. Transplant Proc1997; 29: 290-291.
19.
Shun-Shin GA , Brown NP, Bron AJ, et al. Dynamic nature of posterior subcapsular cataracts. Br J Ophthalmol1989; 73: 522-527.
20.
Chylack LTCataracts and inhaled corticosteroids. N Engl J Med1997; 337: 46-48.
21.
Karim AK, Jacob TJ, Thompson GMThe human lens epithelium; morphologic and ultrastructural changes associated with steroid therapy. Exp Eye Res1989; 48: 215-224.
22.
Harding JJ, Crabbe MJC.The lens: development, proteins, metabolism and cataract. In: Orlando DH (ed.), The eye. Vol 1B, 3rd edn. Academic Press; 1984, pp. 207-492.
23.
McLean JMUse of ACTH and cortisone. Tr Am Ophthalmol Soc1950; 48: 293-296.
24.
Tripathi RC , Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk . Drugs Aging1999; 15: 439-450.
25.
Skuta GL, Morgan RKCorticosteroid-induced glaucoma. In: Ritch R, Shields MB, Krupin T (eds), The glaucomas, 2nd edn. Mosby; 1996, pp. 1177-1188.
26.
Garbe E., LeLoner J., Boivin JF, et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open angle glaucoma. JAMA1997; 277: 722-727.
27.
Akduman L., Kolker AE, Black DL, et al. Treatment of persistent glaucoma secondary to periocular corticosteroids . Am J Ophthalmol1996; 122: 275-277.
28.
Zhang X., Ognibene CM, Clark AF, et al. Dexamethasone inhibition of trabecular meshwork cell phagocytosis and its modulation by glucocorticoid receptor beta. Exp Eye Res2007; 84: 275-284.
29.
Stone EM, Fingert JH, Alward WLM, et al. Identification of a gene that causes primary open angle glaucoma . Science1997; 275: 668-670.
30.
Wiggs JL, Allingham RR, Vollrath D., et al. Prevalence of mutations in TIGR/ myocilin in patients with adult and juvenile primary open-angle glaucoma. Am J Hum Genet1998; 63: 1549-1552.
31.
Kubota R., Kudoh J., Mashima Y., et al. Genomic organization of the human myocilin gene (MYOC) responsible for primary open angle glaucoma (GLC1A). Biochem Biophys Res Commun1998; 242: 396-400.
32.
Armaly MFStatistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response. Invest Ophthalmol1965; 4: 187-197.
33.
Armaly MFEffect of corticosteroids on intraocular pressure and fluid dynamics: The effect of dexamethasone in the normal eye. Arch Ophthalmol1963; 70: 482-491.
34.
Becker B., Hahn KATopical corticosteroids and heredity in primary open angle glaucoma . Am J Ophthalmol1964; 57: 543-551.
35.
Paterson G.Studies of the response to topical dexamethasone of glaucoma relatives. Trans Ophthalmol Soc UK1965; 85: 295-305.
36.
Podos SM, Becker B., Morton WRHigh myopia and primary open-angle glaucoma. Am J Ophthalmol1966; 62: 1039-1043.
37.
Becker B.Diabetes mellitus and primary open angle glaucoma: the XXVII Edward Jackson Memorial Lecture. Am J Ophthalmol1971; 71: 1-16.
38.
Gaston H., Absolon MJ, Thurtle OA, et al. Steroid responsiveness in connective tissue diseases. Br J Ophthalmol1983; 67: 487-490.
39.
Black RL, Oglesby RB, Von Sallmann L., Bunim JJPosterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA1960; 174: 166-171.
40.
Palimeris G. , Koliopoulos J., Velissaropoulos P.Ocular side effects of indomethacin. Ophthalmologica1972; 164: 339-353.
41.
Palimeris G. , Koliopoulos J., Velissaropoulos P.Electrophysiological findings in patients treated with indomethacin. Adv Exp Med Biol1972; 24: 323-329.
42.
Graham CM, Blach RKIndomethacin retinopathy: case report and review. Br J Ophthalmol1988; 72: 434-438.
43.
Groomer AE, Terry JE, Westblom TUSubconjunctival and external hemorrhage secondary to oral anticoagulation . J Am Optom Assoc1990; 61: 770-775.
44.
Mortada A., Abboud I.Retinal haemorrhages after prolonged use of salicylates. Br J Ophthalmol1973; 57: 199-200.
45.
Sharma VK, Sethuraman G., Minz A.Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol2008; 74: 238-240.
Symmons DP, Salmon M., Farr M., et al. Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis. J Rheumatol1988 ; 15: 575-579.
48.
Magnus JH, Elverland HH, Olsen EG, Husby G.Facial palsy and partial accommodative insufficiency associated with sulphasalazine treatment in a patient with ankylosing spondylitis. Scand J Rheumatol1993; 22: 199-201.
49.
Santodomingo-Rubido J., Gilmartin B., Wolffsohn JSDrug-induced bilateral transient myopia with the sulphonamide sulphasalazine. Ophthalmic Physiol Opt2003; 23: 567-570.
50.
Fuentes-Páez G., Mendez MC, Montañez J., et al. Conjunctival pigmentation in Stevens-Johnson syndrome. Ann Ophthalmol2007; 39: 152-157.
51.
Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell co stimulation in patients with psoriasis vulgaris. J Clin Invest1999 ; 103: 1243-1252.
52.
Kremer JM, Westhovens R., Leon M., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med2003; 349: 1907-1915.
53.
Aran AA, Putterman C.Treatment of lupus nephritis: facing the era of immunotherapy. Panminerva Med2008; 50: 235-245.
54.
Genovese MC , Schiff M., Luggen M., et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis2008; 67: 547-554.
55.
Schiff M., Keiserman M., Codding C., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis2008; 67: 1096-1103.
56.
Kremer JM, Genant HK, Moreland LW, et al. Results of a two-year follow-up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum2008; 58: 953-963.
57.
Ruperto N., Lovell DJ, Quartier P., et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet2008; 372: 383-391.
58.
Pescovitz MDRituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant2006; 6: 859-666.
59.
Kimby E.Tolerability and safety of rituximab (MabThera). Cancer Treat Rev2005; 31: 456-473.
60.
Foran JM, Rohatiner AZ, Cunningham D., et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma . J Clin Oncol2000; 18: 317-324.
61.
Lassoued S. , Zabraniecki L., Marin F., Billey T.Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum2007; 36: 262-263.
62.
Fonollosa A. , Segura A., Giralt J., Garcia-Arumi J.Tuberculous uveitis after treatment with etanercept . Graefes Arch Clin Exp Ophthalmol2007; 245: 1397-1399.
63.
Taban M., Dupps WJ, Mandell B., Perez VLEtanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm2006 ; 14: 145-150.
Hayasaka S. , Fujii M., Yamamoto Y., et al. Retinopathy and subconjunctival haemorrhage in patients with chronic viral hepatitis receiving inteferon alfa. Br J Ophthalmol1995; 79: 150-152.
66.
O’Neill DPThe eye and liver disorders. Eye1992; 6: 366-370.
Fukumoto Y. , Shigemitsu T., Kajii N., et al. Abducent nerve paralysis during interferon alpha-2a therapy in a case of chronic active hepatitis C. Intern Med1994; 33: 637-640.
69.
Gillies MC, Garrett SK, Shina SM, Morlet N., Taylor HRTopical interferon alpha 2b for corneal haze after excimer laser photorefractive keratectomy. J Cataract Refract Surg1996; 22: 891-900.
70.
Leyland M., Torok ME, Acheson J., Foster GRHepatitis C virus infection is not associated with a marked increase in the prevalence of ophthalmic morbidity. Eye2000 ; 14: 889-891.
71.
Tokai R., Ikeda T., Miyaura T., Sato K.Interferon-associated retinopathy and cystoid macular edema. Arch Ophthalmol2001; 119: 1077-1079.
72.
Peres-AlvareZ AF, Jimenez-Alonso J., Reche-Molina I., et al. Retinal vasculitis and vitreitis in a patient with chronic hepatitis C virus . Arch Intern Med2001; 161: 2262.
73.
Jain K., Lam WC, Waheeb S., Thai Q., Heathcote J.Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol2001; 85: 1171-1173.
74.
Esmaeli B., Koller C., Papadopoulos N., Romaguera J.Interferon-induced retinopathy in asymptomatic cancer patients. Ophthalmology2001; 108: 858-860.
75.
Willson RL, Ross RD, Willson LM, et al. Interferon-associated retinopathy in a young, insulin dependent diabetic patient. Retina2000; 20: 413-415.
76.
Norcia F., Di Maria A., Prandini F., Redaelli C.Natural interferon therapy: optic nerve ischemic damage?Ophthalmologica1999; 213: 339-340.
77.
Kadayifcilar S., Boyacioglu S., Kart H., Gursoy M., Aydin P.Ocular complications with high-dose interferon alpha in chronic active hepatitis. Eye1999 ; 13: 241-246.
78.
Abe T., Nakajima A., Matsunaga M., Sakuragi S., Komatsu M.Decreased tear lactoferrin concentration in patients with chronic hepatitis C. Br J Ophthalmol1999; 83: 684-687.
79.
Manesis EK, Moschos M., Brouzas D., et al. Neurovisual impairment: a frequent complication of alpha-interferon treatment in chronic viral hepatitis. Hepatology1998; 27: 1421-1427.
80.
Sugano S., Suzuki T., Watanabe M., et al. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol1998; 93: 2441-2444.
81.
Kawano T., Shigehira M., Uto H., et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol1996; 91: 309-313.
Schulman JA , Liang C., Kooragayala LM, King J.Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology2003 ; 110: 437-442.
84.
Hejny C., Sternberg P., Lawson DH, Greiner K., Aaberg TM Jr.Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol2001; 131: 782-787.
85.
Yamada H., Mizobuchi K., Isogai Y.Acute onset of ocular complications with interferon. Lancet1994; 343: 914.
86.
Kuga K., Hasumura S., Nagamori S., Toda G., Kitahara K.Intraocular hemorrhage developing during interferon therapy. Intern Med1996; 35: 15-18.
87.
Al-Tweigeri T., Nabholtz JM, Mackey JROcular toxicity and cancer chemotherapy. Cancer1996; 78: 1359-1373.
88.
Margileth DA , Poplack DG, Pizzo PA, et al. Blindness during remission in two patients with acute lymphoblastic leukemia: a possible complication of multimodality therapy. Cancer1997; 39: 58-61.
89.
Clare G., Colley S., Kennett R., et al. Reversible optic neuropathy associated with low-dose methotrexate therapy. J Neuroophthalmol2005; 25: 109-112.
90.
Whittle SL, Hughes RAFolate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology2004; 43: 267-271.
91.
Ponjavic V. , Granse L., Stigmar EB, et al. Reduced full-field electroretinogram (ERG) in a patient treated with methotrexate. Acta Ophthalmol Scand2004; 82: 96-99.
92.
Razonable RR , Pulido JS, Deziel PJ, et al. Chorioretinitis and vitreitis due to Tropheryma whipplei after transplantation: case report and review. Transpl Infect Dis2008; 10: 413-418.
93.
Hassikou H. , El Haouri M., Tabache M., et al. Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis. Joint Bone Spine2008; 75: 597-599.
94.
de Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis . N Engl J Med2006; 355: 675-684.
95.
Valleala H. , Laitinen K., Pylkkanen L., et al. Clinical and biochemical response to single infusion of clodronate in active rheumatoid arthritis - a double blind placebo controlled study. Inflamm Res2001; 50: 598-601.
96.
Fraunfelder FW, Fraunfelder FTBisphosphonates and ocular inflammation . N Engl J Med2003; 348: 1187-1188.
97.
Fraunfelder FWOcular side effects associated with bisphosphonates . Drugs Today2003; 39: 829-835.
98.
Fraunfelder FW, Fraunfelder FF, Jensvold B.Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol2003; 135: 219-222.
Schadewaldt H.Introduction of atebrine into material medica . Dtsch Med Wochenschrift1975; 100: 2583-2585.
101.
Green R.A report of fifty cases of malaria treated with atebrin. Lancet1932; 1: 826-829.
102.
Schulemann W.Synthetic antimalarial drugs. Br Med J1932; 1: 100-101.
103.
Carr RE, Henkind P., Rothfield N., et al. Ocular toxicity of antimalarial drugs: long term follow-up. Am J Ophthalmol1968; 66: 738-744.
104.
Ansdell VE , Common JDCorneal changes induced by mepacrine . J Trop Med Hyg1979; 82: 206-207.
105.
Chamberlain WP Jr, Boles DJEdema of cornea precipitated by quinacrine (Atabrine). Arch Ophthalmol1946 ; 35: 120-134.
106.
Hobbs HE, Sorsby A., Freedman A.Retinopathy following chloroquine therapy. Lancet1959; 2: 478-480.
107.
Shearer RV , Dubois ELOcular changes induced by long term hydroxychloroquine (Plaquenil) therapy. Am J Ophthalmol1967; 64: 245-252.
108.
Levy GD, Munz SJ, Paschal J., et al. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum1997; 40: 1482-1486.
109.
Klinger G. , Morad Y., Westall CA, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet2001; 358: 813-814.
110.
Yam J. , Kwok A.Ocular toxicity of hydroxychloroquine . Hong Kong Med J2006; 12: 294-304.
111.
Jones SKOcular toxicity and hydroxychloroquine: Guidelines for screening. Br J Dermatol1999; 140: 37.
112.
Marmor MF, Carr RE, Easterbrook M., Farjo AA, Mieler WFRecommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology2002; 109: 1377-1382.
113.
Marmor MFNew American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis Rheum2003; 48: 1764.
114.
Easterbrook M.Screening for antimalarial toxicity: current concepts. Can J Ophthalmol2002; 37: 325-328.
115.
Royal College of Ophthalmologists. http://www.rcophth.ac.uk/docs/publications/published-guidelines/Hydroxychloroquine_and_Ocular_Toxicity_final_Oct_2009.pdf
116.
American College of Rheumatology.Position Statement: Screening for Hydroxychloroquine Retinopathy. http://www.rheumatology.org/publications/position/hydroxy.asp?aud=prs
117.
Grierson DJHydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis1997; 56: 188-190.
118.
Johnson MW , Vine AKHydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol1987; 104: 139-144.
119.
Shroyer NF , Lewis RA, Lupski JRAnalysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy. Am J Ophthalmol2001; 131: 761-766.
120.
Wei LC , Chen SN, Ho CL, Kuo YH, Ho JDProgression of hydroxychloroquine retinopathy after discontinuation of therapy: Case report. Chang Gung Med J2001; 24: 329-334.
